Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 1.00 |
| ▸ | RXRB | P28702 | 9/20 | 0.70 |
| ▸ | RXRG | P48443 | 9/20 | 0.70 |
| ▸ | RARB | P10826 | 7/20 | 0.70 |
| ▸ | RARG | P13631 | 6/20 | 0.70 |
| ▸ | RARA | P10276 | 4/20 | 0.70 |
| ▸ | PPARG | P37231 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.70 |
| ▸ | PGR | P06401 | 1/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.70 |
| ▸ | DRD1 | P21728 | 1/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1073659 | 0.91 | RXRA (0.84) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6890738 | 0.88 | RXRA (0.78) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6905878 | 0.87 | RXRA (0.77) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL20411344 | 0.87 | RXRA (0.76) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7870769 | 0.86 | RXRA (0.75) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6891059 | 0.86 | RXRA (0.75) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL1073669 | 0.85 | RXRA (0.74) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL727936 | 0.85 | RXRA (0.74) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL14782242 | 0.85 | RXRA (0.74) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7030845 | 0.85 | RXRA (0.73) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263189-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | ACADIA PHARMACEUTICALS INC. | 2016-09-15 | — | — | US | claimed |
| WO-2015059632-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | ACADIA PHARMACEUTICALS INC. (US) | 2015-04-30 | — | — | WO | claimed |
| JP-4738738-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| EP-1576089-A4 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD (IL) | 2007-02-14 | — | — | EP | claimed |
| EP-1485464-A4 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA CELL LTD (IL) | 2006-11-29 | — | — | EP | claimed |
| JP-2005528088-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1576089-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | Gamida Cell Ltd. (IL) | 2005-09-21 | — | — | EP | claimed |
| EP-1534820-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | Gamida Cell Ltd. (IL) | 2005-06-01 | — | — | EP | claimed |
| US-20050008624-A1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. | 2005-01-13 | — | — | US | claimed |
| EP-1485464-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | Gamida Cell Ltd. (IL) | 2004-12-15 | — | — | EP | claimed |
| WO-2004016731-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | GAMIDA-CELL LTD. (IL) | 2004-02-26 | — | — | WO | claimed |
| EP-0983991-B1 | Compounds having selectivity for retinoid x receptors | LIGAND PHARM INC (US) | 2003-12-17 | — | — | EP | claimed |
| WO-2003078567-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA-CELL LTD. (IL) | 2003-09-25 | — | — | WO | claimed |
| WO-2003062369-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA-CELL LTD. (IL) | 2003-07-31 | — | — | WO | claimed |
| US-6320074-B1 | IN VIVO MODULATION OF LIPID METABOLISM, SKIN-RELATED PROCESSES, AUTOIMMUNE DISEASES, FATTY ACID METABOLISM, MALIGNANT CELL DEVELOPMENT, PREMALIGNANT LESIONS, OR PROGRAMMED CELL DEATH | LIGAND PHARMACEUTICALS INCORPORATED | 2001-11-20 | — | — | US | claimed |
| EP-0983991-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | claimed |
| EP-0983992-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | claimed |
| EP-0637297-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | claimed |
| WO-1993021146-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1993-10-28 | — | — | WO | claimed |
| US-10391093-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-10328040-B2 | Therapeutic methods | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-06-25 | — | — | US | disclosed |
| US-10238626-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-03-26 | — | — | US | disclosed |
| US-10231947-B2 | Isochroman compounds and methods of use thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180320139-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL INC. | 2018-11-08 | — | — | US | disclosed |
| US-20180207156-A1 | DIHYDROINDENE AND TETRAHYDRONAPHTHALENE COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-07-26 | — | — | US | disclosed |
| US-20180207126-A1 | THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-26 | — | — | US | disclosed |
| US-20180207126-A1 | THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-26 | — | — | US | disclosed |
| US-20180207125-A1 | ISOCHROMAN COMPOUNDS AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-07-26 | — | — | US | disclosed |
| US-20180207125-A1 | ISOCHROMAN COMPOUNDS AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-07-26 | — | — | US | disclosed |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz (US) | 2017-06-29 | — | — | US | disclosed |
| US-9573906-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573906-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160338981-A1 | THERAPEUTIC METHODS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160338981-A1 | THERAPEUTIC METHODS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160263189-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | ACADIA PHARMACEUTICALS INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160097037-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD. | 2016-04-07 | — | — | US | disclosed |
| EP-2910549-A1 | 1,2,3,4-TETRAHYDRO-1,1,4,4-TETRAMETHYLNAPHTHALENE DERIVATIVES USEFUL AS RXR MODULATORS FOR TREATING ALZHEIMER'S DISEASE AND CANCER | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University (US) | 2015-08-26 | — | — | EP | disclosed |
| WO-2015109318-A2 | THERAPEUTIC METHODS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-07-23 | — | — | WO | disclosed |
| WO-2015059632-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | ACADIA PHARMACEUTICALS INC. (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, A body corporate of the State of Arizona, acting for and on | 2014-11-20 | — | — | US | disclosed |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, A body corporate of the State of Arizona, acting for and on | 2014-11-20 | — | — | US | disclosed |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2766018-A2 | RXR AGONISTS COMPOUNDS AND METHODS | Case Western Reserve University (US) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013056232-A2 | RXR AGONISTS COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013056232-A2 | RXR AGONISTS COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013040227-A2 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-2206773-B1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD (IL) | 2012-07-11 | — | — | EP | disclosed |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | LANDRETH GARY E (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | LANDRETH GARY E (US) | 2012-05-10 | — | — | US | disclosed |
| US-7955852-B2 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. (IL) | 2011-06-07 | — | — | US | disclosed |
| EP-2305794-A1 | Expansion of renewable stem cell populations | Gamida Cell Ltd. (IL) | 2011-04-06 | — | — | EP | disclosed |
| US-20110033427-A1 | Expansion Of Renewable Stem Cell Populations | GAMIDA CELL LTD. (IL) | 2011-02-10 | — | — | US | disclosed |
| WO-2011006157-A2 | RXR AGONIST COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-01-13 | — | — | WO | disclosed |
| EP-2206773-A1 | Espansion of renewable stem cell populations | Gamida Cell Ltd. (IL) | 2010-07-14 | — | — | EP | disclosed |
| EP-1576089-B1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD (IL) | 2010-04-14 | — | — | EP | disclosed |
| US-7655699-B1 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors | EISAI INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655699-B1 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors | EISAI INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655699-B1 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors | EISAI INC. (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1799812-A4 | METHODS OF EX VIVO PROGENITOR AND STEM CELL EXPANSION BY CO-CULTURE WITH MESENCHYMAL CELLS | GAMIDA CELL LTD (IL) | 2009-09-09 | — | — | EP | disclosed |
| EP-1649007-A4 | METHODS FOR EX-VIVO EXPANDING STEM/PROGENITOR CELLS | GAMIDA CELL LTD (IL) | 2008-05-14 | — | — | EP | disclosed |
| EP-1799812-A2 | METHODS OF EX VIVO PROGENITOR AND STEM CELL EXPANSION BY CO-CULTURE WITH MESENCHYMAL CELLS | Gamida Cell Ltd. (IL) | 2007-06-27 | — | — | EP | disclosed |
| US-20070082397-A1 | Ex vivo progenitor and stem cell expansion for use in the treatment of disease of endodermally-derived organs | GAMIDA-CELL LTD. (IL) | 2007-04-12 | — | — | US | disclosed |
| US-20070077652-A1 | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells | GAMIDA CELL LTD. | 2007-04-05 | — | — | US | disclosed |
| EP-1576089-A4 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD (IL) | 2007-02-14 | — | — | EP | disclosed |
| EP-1485464-A4 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA CELL LTD (IL) | 2006-11-29 | — | — | EP | disclosed |
| US-20060205071-A1 | Methods for ex-vivo expanding stem/progenitor cells | GAMIDA-CELL LTD. (IL) | 2006-09-14 | — | — | US | disclosed |
| US-20060106072-A1 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors | EISAI INC. | 2006-05-18 | — | — | US | disclosed |
| EP-1649007-A2 | METHODS FOR EX-VIVO EXPANDING STEM/PROGENITOR CELLS | Gamida Cell Ltd. (IL) | 2006-04-26 | — | — | EP | disclosed |
| WO-2006030442-A2 | METHODS OF EX VIVO PROGENITOR AND STEM CELL EXPANSION BY CO-CULTURE WITH MESENCHYMAL CELLS | GAMIDA-CELL LTD. (IL) | 2006-03-23 | — | — | WO | disclosed |
| US-20050220774-A1 | Methods of inducing differentiation in ex vivo expanded stem cells | GAMIDA CELL LTD. (IL) | 2005-10-06 | — | — | US | disclosed |
| EP-1576089-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | Gamida Cell Ltd. (IL) | 2005-09-21 | — | — | EP | disclosed |
| EP-1534820-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | Gamida Cell Ltd. (IL) | 2005-06-01 | — | — | EP | disclosed |
| US-20050054097-A1 | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures | GAMIDA CELL LTD. (IL) | 2005-03-10 | — | — | US | disclosed |
| WO-2005007799-A2 | METHODS FOR EX-VIVO EXPANDING STEM/PROGENITOR CELLS | GAMIDA-CELL LTD. (IL) | 2005-01-27 | — | — | WO | disclosed |
| US-20050008624-A1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. | 2005-01-13 | — | — | US | disclosed |
| EP-1485464-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | Gamida Cell Ltd. (IL) | 2004-12-15 | — | — | EP | disclosed |
| US-20040162354-A1 | Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2004-08-19 | — | — | US | disclosed |
| WO-2004016731-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | GAMIDA-CELL LTD. (IL) | 2004-02-26 | — | — | WO | disclosed |
| EP-0983991-B1 | Compounds having selectivity for retinoid x receptors | LIGAND PHARM INC (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6646008-B1 | Administering peroxisome proliferator activated receptor(PPAR) and retinoid acid receptor agonists such as 6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl) nicotinic acid, for prophylaxis of tumors | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2003-11-11 | — | — | US | disclosed |
| WO-2003078567-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA-CELL LTD. (IL) | 2003-09-25 | — | — | WO | disclosed |
| US-6610883-B1 | Such as 3-methyl-5-(2-(2-(2,6,6-trimethylcyclohexen-1-yl)-ethenyl)phenyl)-2,4 -pentadienoic acid | LIGAND PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| WO-2003062369-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA-CELL LTD. (IL) | 2003-07-31 | — | — | WO | disclosed |
| US-6586455-B1 | Administering retinoid and peroxisome proliferator-activated receptors to improve cell proliferation and differentiation of adipocytes; prophylaxis of cancer | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2003-07-01 | — | — | US | disclosed |
| US-6320074-B1 | IN VIVO MODULATION OF LIPID METABOLISM, SKIN-RELATED PROCESSES, AUTOIMMUNE DISEASES, FATTY ACID METABOLISM, MALIGNANT CELL DEVELOPMENT, PREMALIGNANT LESIONS, OR PROGRAMMED CELL DEATH | LIGAND PHARMACEUTICALS INCORPORATED | 2001-11-20 | — | — | US | disclosed |
| US-6043279-A | COMPOUNDS USED FOR IN VIVO MODULATION OF LIPID METABOLISM, SKIN-RELATED PROCESSES, MALIGNANT CELL DEVELOPMENT, PREMALIGNANT LESIONS, PROGRAMMED CELL DEATH | LIGAND PHARMACEUTICALS, INCORPORATED (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0983991-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | disclosed |
| EP-0983992-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | disclosed |
| US-5962731-A | MODIFY LIPID METABOLISM; SKIN DISORDERS,; AUTOIMMUNE DISEASES; FATTY ACID METABOLISM; ANTITUMOR AGENTS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0678087-B1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARM INC (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5780676-A | BICYCLIC BENZYL, PYRIDINYL, THIOPHENE, FURANYL, PYRROLE, AND POLYENOIC ACID DERIVATIVES | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0678086-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0678087-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0637297-A4 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS. | LIGAND PHARM INC (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995004036-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| EP-0637297-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994015902-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994015901-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1993021146-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993021146-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238626-B2 | Therapeutic compounds | PSEN1, MAPT, APP | RXRA 2056/4885RXRB 2070/4885RXRG 1742/4885 |
| US-10391093-B2 | Therapeutic compounds | PSEN1, PSEN2, MAPT | RXRA 3433/4885RXRB 3366/4885RXRG 2932/4885 |
| US-10231947-B2 | Isochroman compounds and methods of use thereof | MAG, IDH3A, IPO5 | RXRA 2102/4885RXRB 2464/4885RXRG 2174/4885 |
| US-20060106072-A1 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors | RXRB, RXRA, RXRG | RXRA 2/4885RXRB 1/4885RXRG 3/4885 |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | PSEN1, PSEN2, MAPT | RXRA 3433/4885RXRB 3366/4885RXRG 2932/4885 |
| US-20180207125-A1 | ISOCHROMAN COMPOUNDS AND METHODS OF USE THEREOF | MAG, IDH3A, IPO5 | RXRA 2102/4885RXRB 2464/4885RXRG 2174/4885 |
| US-20180207126-A1 | THERAPEUTIC COMPOUNDS | PSEN1, MAPT, APP | RXRA 2056/4885RXRB 2070/4885RXRG 1742/4885 |
| US-20180207156-A1 | DIHYDROINDENE AND TETRAHYDRONAPHTHALENE COMPOUNDS | DHPS, DHODH, APP | RXRA 3174/4885RXRB 3240/4885RXRG 3620/4885 |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | MAPT, PSEN1, PSEN2 | RXRA 3109/4885RXRB 2990/4885RXRG 2381/4885 |
| US-20160263189-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | NCOR1, NR4A2, NR4A3 | RXRA 4/4885RXRB 7/4885RXRG 13/4885 |
| US-20160338981-A1 | THERAPEUTIC METHODS | RXRG, RXRB, RXRA | RXRA 3/4885RXRB 2/4885RXRG 1/4885 |
| US-20040162354-A1 | Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor | PPARA, PPARG, PPARD | RXRA 6/4885RXRB 5/4885RXRG 4/4885 |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | RXRA 1/4885RXRB 2/4885RXRG 3/4885 |
| US-10328040-B2 | Therapeutic methods | RXRG, RXRB, RXRA | RXRA 3/4885RXRB 2/4885RXRG 1/4885 |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | RXRA 1/4885RXRB 2/4885RXRG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.